Click here to go to the previous page
Global Clinical Trials: The Role of Emerging Markets
Program Code:
126
Date:
Monday, June 24, 2013
Time:
2:30 PM to 4:00 PM
EST
CHAIR
:
Nancy has held various research and management positions with pharma and CROs. She has expertise is establishing and leading teams of clinical research professionals in Europe, North America, Latin America and AsiaPacific.
|
SPEAKER
(S):
Nancy Meyerson-Hess, MSc (SPKNON), Compound Development and Branding, Gruenenthal, Germany
Guei-Jen Shieh,
PhD (SPKSUP), Director, Clinical Group,
National Research Program For Biopharmaceuticals, Taiwan
Dr. Guei-Jen Shieh is the director of Clinical Group at NRPB (National Research Program for Biopharmaceuticals) Office, with responsibility for overseeing and managing clinical researches in new drug/device development. She previously worked for a CRO, the Center for Drug Evaluation, and Taiwan DOH.
|
Linda Martin,
MBA (SPKNON), Principal and Founder,
KMR Group Inc., United States
Scott Martin is Principal of KMR Group a firm specializing on biopharmaceutical R&D performance, information and analytics. His areas of expertise include clinical development performance, R&D productivity, and enrollment optimization. Scott received his JD from the University of Chicago.
|
Description
Today's drug development relies on global clinical trials which include emerging markets. The symposium will address performance, best practices, strategies and challenges of undertaking global clinical trials. The speakers will provide examples from global clinical trials with a focus on reducing risks, optimizing strategy to improve site enrollment and overall performance, and experience from the Clinical Trial Consortium in the Asia Pacific region.